Sarah Catoen

Title: The Innovations of Sarah Catoen

Introduction

Sarah Catoen is an accomplished inventor based in Livry-Gargan, France. She has made significant contributions to the field of medical imaging, particularly in the development of radiolabeled compounds for cancer diagnosis and treatment.

Latest Patents

Catoen holds a patent for a radiolabeled macrocyclic EGFR inhibitor. This invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging epidermal growth factor receptors (EGFR). The patent outlines their use in in vivo diagnosis, preclinical and clinical tumor imaging, and patient stratification based on the mutational status of EGFR. It also describes methods for preparing the radiotracers and is relevant to various cancers influenced by deregulated EGFR, including non-small cell lung cancer, pancreatic cancer, and breast cancer.

Career Highlights

Catoen is currently employed at Oncodesign SA, where she continues to advance her research in cancer diagnostics. Her work has the potential to significantly impact the way tumors are diagnosed and treated, improving patient outcomes.

Collaborations

Some of her notable coworkers include Jan Marie Cyriel Jozef Hoflack and Cyril Berthet, who contribute to her innovative projects and research initiatives.

Conclusion

Sarah Catoen's work exemplifies the intersection of innovation and healthcare, showcasing how her inventions can lead to better diagnostic tools for cancer treatment. Her contributions are paving the way for advancements in medical imaging and patient care.